Lavipharm (ATH:LAVI) FCF Margin % : -19.31% (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Lavipharm FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Lavipharm's Free Cash Flow for the six months ended in Dec. 2023 was €-4.15 Mil. Lavipharm's Revenue for the six months ended in Dec. 2023 was €21.47 Mil. Therefore, Lavipharm's FCF Margin % for the quarter that ended in Dec. 2023 was -19.31%.

As of today, Lavipharm's current FCF Yield % is -2.66%.

The historical rank and industry rank for Lavipharm's FCF Margin % or its related term are showing as below:

ATH:LAVI' s FCF Margin % Range Over the Past 10 Years
Min: -82.63 Med: 1.42 Max: 5.52
Current: -7.53

During the past 7 years, the highest FCF Margin % of Lavipharm was 5.52%. The lowest was -82.63%. And the median was 1.42%.

ATH:LAVI's FCF Margin % is ranked worse than
66.57% of 1023 companies
in the Drug Manufacturers industry
Industry Median: 0.25 vs ATH:LAVI: -7.53

Lavipharm FCF Margin % Historical Data

The historical data trend for Lavipharm's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lavipharm FCF Margin % Chart

Lavipharm Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

1.42

3.65

5.52

-82.63

-7.53

Lavipharm Semi-Annual Data
	Dec17	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial					5.81	9.16	-191.57	1.06	-19.31

Competitive Comparison of Lavipharm's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Lavipharm's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lavipharm's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lavipharm's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Lavipharm's FCF Margin % falls into.

Lavipharm FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Lavipharm's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-3.833	/	50.929
	=	-7.53 %

Lavipharm's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-4.146	/	21.474
	=	-19.31 %

Lavipharm FCF Margin % Related Terms

Thank you for viewing the detailed overview of Lavipharm's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lavipharm (ATH:LAVI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lavipharm SA (ATH:LAVI) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BXA0:Germany

Address

Agias Marinas Street, PO Box 59, Peania Attica, GRC, 19002

Website

http://www.lavipharm.com

Lavipharm SA develops, manufactures, markets and distributes pharmaceutical, cosmetic and consumer health products in Greece and internationally. The company's product portfolio includes innovative, safe and effective therapeutic solutions that meet consumer' needs for health and wellbeing. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, General Medicine, Self- Treatment and Dermocosmetic care.

Lavipharm (ATH:LAVI) Headlines

No Headlines